News

Filter

Current filters:

GenmabLicensing

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

10-09-2014

Biotech companies Seattle Genetics of the USA and Denmark’s Genmab have entered into an additional…

BiotechnologyGenmabHuMax-TACLicensingOncologyResearchSeattle Genetics

Genmab and ADC Thera link for antibody drug conjugate combining HuMax-TAC and PBD warhead

18-06-2013

Denmark's Genmab (OMX: GEN) and Switzerland-based ADC Therapeutics have entered an agreement to develop…

ADC TherapeuticsBiotechnologyGenmabHuMax-TACLicensingOncologyResearch

Genmab leaps on $1.1 billion daratumumab deal with Janssen

31-08-2012

Denmark's Genmab A/S (OMX: GEN) saw its shares leap 20% to 81 Danish kroner in morning trading yesterday,…

BiotechnologydaratumumabFinancialGenmabHuMax-CD38JanssenJohnson & JohnsonLicensingOncologyPharmaceutical

Genmab in collaboration with Janssen for DuoBody platform

16-07-2012

Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

Denmark’s Lundbeck buys rights to Merck & Co’s antipsychotic Sycrest; enters deal with Genmab

13-10-2010

Danish drugmaker Lundbeck A/S (LUND: DC) announced a worldwide commercialization agreement with US drugs…

GenmabLicensingLundbeckMerck & CoNeurologicalPharmaceuticalSaphrisSycrest

Denmark’s Genmab updates on corporate strategy; licenses ADC technology from Seattle Genetics

15-09-2010

Danish biotech firm Genmab A/S (OMX: GEN) yesterday announced an update to its corporate strategy saying…

BiotechnologyGenmabLicensingManagementOfatumumab InjectionOncologyPharmaceuticalResearchSeattle Geneticszalutumumab

GlaxoSmithKline amends ofatumumab deal with Genmab; sells Italian research center to Aptuit

02-07-2010

UK drugs giant GlaxoSmithKline has amended its agreement with Denmark’s Genmab A/S for the co-development…

AptuitArzerraBiotechnologyFinancialGenmabGlaxoSmithKlineLicensingNeurologicalOfatumumab InjectionOncologyPharmaceutical

COMPANY SPOTLIGHT

Menarini

Back to top